Siemens Energy India gets NSE & BSE approval for listing & trading its equity shares effective June 19
By Aditya Bhagchandani Published on June 18, 2025, 20:54 IST
Siemens Limited has officially announced that its subsidiary, Siemens Energy India Limited (SEIL), will be listed on the stock exchanges on Thursday, June 19, 2025. The equity shares will be admitted to trading on both BSE and NSE, following approvals from the exchanges.
In a filing, Siemens stated:
'SEIL has informed Siemens Limited today that SEIL has received approval from BSE Limited and the National Stock Exchange of India Limited for listing and trading of its equity shares effective 19th June, 2025.'
The listing follows the Scheme of Arrangement initiated last year to demerge the energy business from Siemens Limited, a move intended to unlock shareholder value and enhance business focus. Key listing details: Listing Date: Thursday, June 19, 2025
Special Pre-open Session: 9:15 AM – 9:45 AM
Regular Trading Begins: 10:00 AM
Segment: 'T' Group (Trade-for-Trade) for the first 10 sessions
ISIN: INE1NPP01017
Number of Shares: 35.6 crore Price Discovery:
While a dummy price of ₹2,478/share was discovered on April 7, 2025, this was for indicative purposes. Fresh price discovery will occur on listing day during the pre-open session, which will determine the actual opening price for SEIL shares.
This marks a significant step for Siemens' energy business in India, offering shareholders a direct avenue to invest in one of the country's key energy solutions providers.
Ahmedabad Plane Crash
Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
7 hours ago
- Business Upturn
Siemens Energy India gets NSE & BSE approval for listing & trading its equity shares effective June 19
By Aditya Bhagchandani Published on June 18, 2025, 20:54 IST Siemens Limited has officially announced that its subsidiary, Siemens Energy India Limited (SEIL), will be listed on the stock exchanges on Thursday, June 19, 2025. The equity shares will be admitted to trading on both BSE and NSE, following approvals from the exchanges. In a filing, Siemens stated: 'SEIL has informed Siemens Limited today that SEIL has received approval from BSE Limited and the National Stock Exchange of India Limited for listing and trading of its equity shares effective 19th June, 2025.' The listing follows the Scheme of Arrangement initiated last year to demerge the energy business from Siemens Limited, a move intended to unlock shareholder value and enhance business focus. Key listing details: Listing Date: Thursday, June 19, 2025 Special Pre-open Session: 9:15 AM – 9:45 AM Regular Trading Begins: 10:00 AM Segment: 'T' Group (Trade-for-Trade) for the first 10 sessions ISIN: INE1NPP01017 Number of Shares: 35.6 crore Price Discovery: While a dummy price of ₹2,478/share was discovered on April 7, 2025, this was for indicative purposes. Fresh price discovery will occur on listing day during the pre-open session, which will determine the actual opening price for SEIL shares. This marks a significant step for Siemens' energy business in India, offering shareholders a direct avenue to invest in one of the country's key energy solutions providers. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Business Upturn
7 hours ago
- Business Upturn
Morepen Laboratories incorporates wholly owned subsidiary in Dubai to expand pharma trade operations
By Aditya Bhagchandani Published on June 18, 2025, 20:48 IST Morepen Laboratories Limited has announced the incorporation of a wholly owned subsidiary in Dubai, United Arab Emirates. The new entity, Morepen Labs – FZCO, has been officially registered on June 18, 2025, in the Free Zone jurisdiction of Dubai. The company stated in a regulatory filing, 'We are pleased to inform that 'MOREPEN LABS – FZCO', a wholly owned subsidiary of the company, has been incorporated today i.e., 18th June, 2025, in Free Zone, Dubai, United Arab Emirates.' This move marks a significant step in Morepen's international expansion strategy. The subsidiary has been established with an authorized capital of AED 50,000, comprising 5,000 ordinary shares of AED 10 each. Morepen will hold 100% ownership in this newly formed entity. According to the company, 'The incorporated entity being a wholly owned subsidiary, is a related party of the company. The promoter/ promoter group do not have any interest in the newly formed entity.' Morepen Labs – FZCO will primarily focus on trading pharmaceuticals and medicines outside the UAE, aligning with the core business of its parent organization. The filing further clarified that no governmental or regulatory approvals were required for this incorporation, and the acquisition was executed through cash consideration. This expansion is expected to strengthen Morepen Laboratories' global footprint and position the company for broader access to international markets in the pharmaceutical trade domain. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Business Upturn
10 hours ago
- Business Upturn
Zydus completes USFDA inspection at oncology plant with two minor observations, none related to data integrity
By Aditya Bhagchandani Published on June 18, 2025, 16:48 IST Zydus Lifesciences Ltd has announced the successful conclusion of a Good Manufacturing Practices (GMP) follow-up inspection by the United States Food and Drug Administration (USFDA) at its oncology injectable manufacturing facility located at SEZ 1, near Matoda, Ahmedabad. The inspection was conducted over a 10-day period, from June 9 to June 18, 2025. In a regulatory filing to the stock exchanges, the company stated, 'We wish to inform that the US Food and Drug Administration (USFDA) conducted a GMP follow-up inspection at the company's oncology injectable site situated at SEZ 1, near Matoda, Ahmedabad.' The company further added that the inspection concluded with two observations, emphasizing that 'none of them were related to data integrity.' Zydus assured stakeholders that it is taking these observations seriously and is committed to addressing them promptly. 'The Company will closely work with the USFDA to address and respond to the observations in an expeditious manner,' the statement read. This update has been provided in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Zydus also requested that this development be 'brought to the notice of the members of the exchange and the investors at large.' The successful closure of the inspection without any data integrity issues is a positive sign for Zydus, reaffirming its compliance with global manufacturing standards in a critical therapeutic segment. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
